Minerva Sees Positive Phase 1 Data for MIN-202 for Insomnia
Minerva Neurosciences Inc’s preliminary results from a Phase 1 clinical study showed that treatment with MIN-202, a selective orexin-2 antagonist, resulted in significant improvements in sleep onset and sleep duration in...
Read More